Research into chronic myeloid leukaemia (CML)

Researchers around the world are looking at improving the treatment of chronic myeloid leukaemia (CML).

Go to Cancer Research UK’s clinical trials database if you are looking for a trial for CML in the UK. You need to talk to your specialist if there are any trials that you think you might be able to take part in.

Some of the trials on this page have now stopped recruiting people. It takes time before the results are available. This is because the trial team follow the patients for a period of time and collect and analyse the results. We have included this ongoing research to give examples of the type of research being carried out in CML.

Research and clinical trials

All cancer treatments must be fully researched before they can be used for everyone. This is so we can be sure that:

  • they work

  • they work better than the treatments already available

  • they are safe

To make sure the research is accurate, each trial has certain entry conditions for who can take part. These are different for each trial.

Hospitals do not take part in every clinical trial. Some trials are only done in a small number of hospitals, or in one area of the country. You may need to travel quite far if you take part in these trials. 

Treatment

The main treatment for CML is a group of targeted cancer drug called tyrosine kinase inhibitors (TKIs).

Targeted cancer drugs

Doctors currently use imatinib, nilotinib, dasatinib, bosutinib and ponatinib to treat CML. Researchers continue to look into these drugs to improve treatment results.

Trials are looking at:

  • trying new TKIs such as asciminib and vodobatinib
  • finding out if one of the TKIs is better than the others as a first treatment for CML
  • trying these TKIs in children and young adults
  • learning more about the dose and side effects
  • finding out more about having a treatment break

Stem cell transplants

A small number of people have a stem cell transplant Open a glossary item as part of your treatment for CML. With CML you have a transplant using stem cells or bone marrow from someone else. This is called a donor or allogeneic transplant Open a glossary item.

Find out about some of the ways researchers are looking to improve them.

Recovery after a stem cell transplant

The immune system Open a glossary item doesn’t work properly for several months after a transplant. It can take a long time for people to recover and they are more prone to getting an infection.

People living with blood cancers often have antibiotics Open a glossary item many times due to their increased risk of infection. Antibiotics can reduce the number of ‘good’ bacteria in the digestive system which reduces the variety of gut microbiome Open a glossary item. Research is looking at treatment to bring back the ‘good’ bacteria to support a person’s immune system and help recovery.

Graft versus host disease (GvHD)

Graft versus host disease (GvHD) is a possible complication of a stem cell transplant from another person. GvHD happens when particular types of white blood cells Open a glossary item (T cells) in the donated stem cells attack your own bodies cells. This is because the donated cells (the graft) see your body cells (the host) as foreign and attack them.

This trial is comparing standard treatment Open a glossary item with 2 newer combinations of treatment to try and see if this helps prevent GvHD.

Improving stem cell transplants

A hospital in Birmingham is looking at people who are having a stem cell transplant and people who are donors of stem cell transplant. They are looking at blood samples before and after a transplant. They are also taking blood from donors.

The researchers want to look further at these samples to better understand stem cell transplants. They hope by having a better understanding of stem cell transplants they can improve the success of treatment and ways to help prevent or lower the side effects.

Related links